University Clinical Centre Hamburg Eppendorf

Prof. Lohse, Clinical Director of the 1st Medical Clinic and Polyclinic (Gastroenterology with the Infectiology and Tropical Medicine sections) at the University Clinical Centre Hamburg Eppendorf and his team analysed more than 1100 blood samples from employees using the Anti-SARS-CoV-2 ELISA IgG. At a press conference on 22 April 2020 he reported on the results and summarised as follows: “The test appears to be specific, even very specific.”

University Clinic Bonn “Heinsberg study”

The “Heinsberg study” was realised in the municipality of Gangelt (North Rhine-Westphalia) by Prof. Dr. Hendrik Streeck and Prof. Dr. Gunther Hartmann from the University of Bonn and their research team. More than 900 persons were tested for COVID-19, among others using the Anti-SARS-CoV-2 ELISA. The study confirmed the high specificity of the EUROIMMUN ELISA and showed a good correlation with a neutralisation assay.

Study results


Quest Diagnostics

Quest Diagnostics, one of the largest laboratory chains worldwide is convinced of the good quality of the Anti-SARS-CoV-2 ELISA (IgG) after performing their own validation studies and now uses the EUROIMMN ELISA in the testing of blood samples for infections with SARS-CoV-2 (COVID-19).

Presse release Quest Diagnostics


Beaumont Health

Beaumont Health, the largest healthcare provider in Michigan, US, has performed internal validation studies on the EUROIMMUN Anti-SARS-CoV-2 ELISA IgG and now uses it for the most comprehensive serological study in the US. First, 38,000 employees of Beaumont and patients shall be tested. Subsequently, the test systems shall also be provided to other hospitals.

Press release Beaumont Health


ARUP Laboratories

ARUP Laboratories, a leading national reference laboratory in the US with customers all over the country, has been using the Anti-SARS-CoV-2 ELISA (IgG) as a second antibody test for COVID-19 diagnostics since 13th May 2020. “The EUROIMMUN test can also help clinicians understand the level of the antibody response and the duration of long-lasting immunity to the disease” says ARUP’s chief medical officer Julia Delgado in their press release.

Press release ARUP Laboratories


Sonora Quest Laboratories

On 8th May 2020, Sonora Quest Laboratories, the market share leader in diagnostic laboratory testing in Arizona, announced they have started performing COVID-19 antibody tests. Sonora Quest also opted to use the Anti-SARS-CoV-2 ELISA (IgG). The laboratory stated they will start off by performing approximately 3,000 determinations per day and expand their capacities step by step.

Press release Sonora Quest Laboratories


LabCorp

LabCorp, a leading global life sciences company with headquarters in the US, has also opted to use the Anti-SARS-CoV-2 ELISA (IgG) from EUROIMMUN and has been offering a “Return to Work” service for employers since 14th May. This includes, among other services, testing for antibodies against the new coronavirus using a kit for at-home sampling by the user (collection of a blood drop from the fingertip) and the subsequent laboratory blood analysis by means of the EUROIMMUN ELISA.

Press release LabCorp


Public Health England

Also Public Health England, an executive agency of the Department of Health and Social Care in the United Kingdom are now applying the EUROIMMUN-Anti-SARS-CoV-2 ELISA (IgG) to monitor the seroprevalence of anti-SARS-CoV-2 antibodies in the British population.

Report Public Health England


Indian Council of Medical Research (ICMR)

On 4th June, the Indian Council of Medical Research (ICMR), one of the most relevant medical institutions in India and central Institution in the fight against the COVID-19 pandemic, declared that they have validated three test systems for the detection of IgG antibodies against SARS-CoV-2, among others the EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG), and approved them for seroprevalence studies on SARS-CoV-2 in population groups at risk in India.

The article


Publications

  1. Beavis et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies. Journal of Clinical Virology 2020
  2. Bond et al. Evaluation of serological tests for SARS-CoV-2: Implications for serology testing in a low-prevalence setting. Preprint medRxiv. 2020
  3. Emmenegger et al. Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay. Preprint medRxiv 2020
  4. GeurtsvanKessel et al. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment. Preprint medRxiv. 2020
  5. Harvala et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Preprint medRxiv. 2020
  6. Kohmer et al. Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunity. bioRxiv. 2020
  7. Lippi et al. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clin Chem Lab Med. 2020
  8. Matushek et al. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. bioRxiv preprint. 2020
  9. Meyer et al. Validation of a commercially available SARS-CoV-2 serological immunoassay. Preprint medRxiv. 2020
  10. Montesinos et al. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol. 2020
  11. Padoan et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta 507:164-166. 2020
  12. Streeck et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. 2020 
  13. Stringhini et al. Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland. Preprint medRxiv 2020.
  14. Theel et al. Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. J Clin Microbiol. 2020
  15. Traugott et al. Performance of SARS-CoV-2 antibody assays in different stages of the infection: Comparison of commercial ELISA and rapid tests. Inf Dis. 2020
  16. Tré-Hardy et al. Validation of a chemiluminescent assay for specific SARS-CoV-2 antibody. Clin Chem Lab Med. 2020